What question did this study set out to answer?

The study aims to analyze the prevalence of cyp51A variants and their role in triazole antifungal resistance.

April 23, 2026Journal of Antimicrobial Chemotherapy0 citations

Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance

LLLuisa Fernanda Gómez LondoñoSt. Jude Children's Research Hospital ASAna Camila Oliveira SouzaSt. Jude Children's Research Hospital BBBrooks BurtBroad Institute

Key Points

The study aims to analyze the prevalence of cyp51A variants and their role in triazole antifungal resistance.
Analyzed clinical isolates of Aspergillus fumigatus from the US for cyp51A mutations.
Conducted a comparative assessment of these mutations' impact on triazole antifungal efficacy.
Documented a range of cyp51A mutations contributing to triazole resistance.
Highlighted that many cases of resistance remain unexplained by known genetic factors.

Abstract

Our findings demonstrate the range of mutations affecting triazole resistance among US isolates and provide a much-needed side-by-side comparison of the impact of these variants on the most currently used mould-active triazole antifungals. Moreover, they underscore the extent to which triazole resistance remains unexplained by known genetic determinants and the need for further discovery.

Demander à l'IA

Bookmark

View Full Paper